Bicycle Therapeutics PLC (BCYC)
- Sector
- Biotechnology
- Last price
- $3.88
- As of
Kresmion compiles this page from BCYC's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
BICYCLE THERAPEUTICS PLC (BCYC): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-20.
See the full BCYC dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for BCYC on one page. Preview it with sample data, then open it live with a free account.
Preview the BCYC dossierActive events for BCYC
- high13F: funds added
4 tracked funds increased BCYC this 2026Q2, institutional consensus
- high13F: large increase
CITADEL ADVISORS LLC added +319% to BCYC (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +4036% to BCYC (2026Q2)
- high13F: funds added
3 tracked funds increased BCYC this 2026Q2, institutional consensus
- high13F: large increase
MILLENNIUM MANAGEMENT LLC added +95% to BCYC (2026Q2)
FREE, NO ACCOUNT
Every event on BCYC, as it fires
You are seeing 5 of 14 events recorded on BCYC since 2026-06-12.
The five above landed across 2 days. The other 9 were recorded on 3 other days. 7 of the 14 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in BCYC (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 088786108 · 2026Q2 | $6.5M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 088786108 · 2026Q2 | $2.3M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 088786108 · 2026Q2 | $2.3M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 088786108 · 2026Q2 | $1.8M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 088786108 · 2026Q2 | $636K | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 088786108 · 2026Q2 | $108K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, BCYC
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
BCYC against its peers
BCYC's operating margin of -340.4% ranks in the 50th percentile of 12 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | BCYC | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 72.6M USD | 6.2M USD | 77 | 14 |
| Operating margin | -340.4% | -838.6% | 50 | 12 |
| Net margin | -301.7% | -436.5% | 54 | 13 |
| Return on equity | -35.9% | -53.2% | 55 | 20 |
Peers (22): CABA, OCGN, RCKT, QTTB, ABEO, FATE, LRMR, LCTX, VNDA, IMRX, NWBO, ACIU, SABS, GLSI, IPSC, PALI, LYEL, IFRX, LXEO, SLGL, IKT, ARCT. Left out: VCRE (no annual filing), CUVL (no annual filing), VOGX (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (BCYC: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow BCYC on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to BCYC for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.